CMP: ₹ 230

Target: ₹ 280(22%)

Target Period: 12 months



BUY

September 25, 2024

Chalks out strategic goals for the future...

About the stock: Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates in 3 major segments. - 1) Contract development and manufacturing organisations (CDMO), 2) Complex hospital generics (critical care), 3) Consumer healthcare (OTC). PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with Allergan, and 33.33% in Yapan Bio which operates in the biologics / bio-therapeutics and vaccine segments.

Analyst Meet Update: (Focus mainly on long term guidance)

- FY30 guidance- Doubling of revenues to US\$ 2 billion with around 25% EBITDA Margins. This translates in to revenues and EBITDA CAGR of ~13% and ~23% respectively between FY24-FY30E. Higher EBITDA growth would be attributable to 1) Better overall operating leverage on the back of better capacity utilisation, 2) significant tilt towards innovative pie in CDMO services with focus on integrated and differentiated services.
- CDMO revenues to be around US\$ 1.2 billion (CAGR of ~13%) with 25% EBITDA margins leveraging on its globally diversified network of facilities across 3 continents. In complex hospital generics, the company aspires to reach US\$ 600 million revenues (CAGR of ~13%) with 25%+ EBITDA margins. In ICH segment the company aims to scale up revenues at a 9% CAGR to US\$ 200 million in the next six years and achieve double-digit EBITDA margins by optimizing expenses.
- Piramal's innovative CDMO segment is seeing early signs of improvement in biotech funding and the management is focusing on improving capacity utilization of existing sites and scale up innovation CDMO business.
- Net debt/EBITDA target is set at 1x and ROCE in High teens. and Tax rate at the consolidated level likely to go down over the next 3-4 years. The growth capex would be calibrated and only after considering the segmental requirement with an eye on leverage and FCF

The company has given long term guidance in an open forum breaking it segment wise. This is mainly organic growth guidance based on global capacities and capabilities (excluding some licensing requirements). The guidance also excludes potential windfall from the implications of Biosecure Act. The core of the guidance is based on offering or differentiated services, offering vertically integrated model and a tilt towards innovation related offerings. We believe the guidance is measured with scope for positive surprises.

Rating and Target price


We now value PPL at ₹ 280 based on SoTP valuations, i.e. 23x FY26E CDMO EBITDA (earlier 20x), 18x FY26E CHG EBITDA (earlier 15x), 1.5x FY26E Consumer Healthcare Sales (earlier 1x), and 10x PAT from AbbVie JV.



Particulars	
Particular	Amount
Market Capitalisation	₹ 30428 crore
Debt (FY24)	₹ 4710 crore
Cash (FY24)	₹ 357 crore
EV	₹ 34781 crore
52 week H/L	244/87
Equity capital	₹ 1323 crore
Face value	₹ 10

Shareholding pattern						
Particular	Sep-23	Dec-23	Mar-24	Jun-24		
Promoters	35.0	35.0	35.0	35.0		
FIIs	32.4	32.5	30.6	32.5		
Dlls	8.0	9.7	12.1	9.7		
Others	24.6	22.8	22.3	22.8		

Price Chart



Key risks

(i) Higher sensitivity of CDMO business towards overall performance.

(ii) Price Erosion and supply issues in CHG

Research Analyst

Siddhant Khandekar siddhant.khandekar@icicisecurities.com

Shubh Mehta shubh.mehta@icicisecurities.com

Vedant Nilekar vedant.nilekar@icicisecurities.com

Key Financial Summary							
(₹ Crore)	FY22	FY23	FY24	CAGR FY22-24 (%)	FY25E	FY26E	CAGR FY24-26 (%)
Revenues	6559.1	7081.6	8171.2	11.6	9231.4	10423.2	12.9
EBITDA	949.7	628.2	1196.3	12.2	1397.9	1862.2	24.8
EBITDA Margins (%)	14.5	8.9	14.6		15.1	17.9	
Net Profit	376.0	-186.5	17.8	-78.2	127.6	519.6	440.0
Adjusted EPS (₹)	3.0	-1.4	0.6		1.0	3.9	
PE (x)	80.8	-162.8	1703.7		238.0	58.4	
EV/EBITDA (x)	36.0	56.3	28.9		24.5	18.1	
RoCE (%)	5.9	1.4	5.0		5.4	8.7	
RoE (%)	5.8	-2.7	1.0		1.6	6.1	

Source: Company, ICICI Direct Research

Financial Summary

Exhibit 3: Profit and loss st	atomont			₹ crore
(Year-end March)/ (₹ crore)	FY23	FY24	FY25E	FY26E
Total Operating Income	7,081.6	8,171.2	9,231.4	10,423.2
Growth (%)	8.0	15.4	13.0	12.9
Raw Material Expenses	1,682.5	1,976.8	1,612.5	1,633.8
Gross Profit	4,378.3	5,217.2	5,987.6	6,890.8
Gross Profit Margins (%)	61.8	63.8	64.9	66.1
Employee Expenses	1,896.4	2,029.5	2,254.9	2,411.6
Other Expenditure	1,853.7	1,991.4	2,334.8	2,617.0
Total Operating Expenditure	6,453.3	6,974.9	7,833.4	8,561.0
EBITDA	628.2	1,196.3	1,397.9	1,862.2
Growth (%)	-33.8	90.4	16.9	33.2
Interest	344.2	448.5	413.2	359.9
Depreciation	676.7	740.6	800.7	864.1
Other Income	225.1	175.4	94.1	107.7
PBT before Exceptional Item	-167.5	182.6	278.0	746.0
Less: Exceptional Items	7.0	62.8	0.0	0.0
PBT after Exceptional Items	-174.5	119.8	278.0	746.0
Total Tax	66.3	161.5	215.9	298.4
PAT before MI	-240.8	-41.7	62.1	447.6
PAT	-186.5	17.8	127.6	519.6
Growth (%)	-149.6	-109.6	615.8	307.3
EPS (Adjusted)	-1.4	0.6	1.0	3.9
Other income as % of (Cash+i	27%	24%	17%	19%

Exhibit 4: Cash flow stateme	nt			₹ crore
(Year-end March)/ (₹ crore)	FY23	FY24	FY25E	FY26E
Profit/(Loss) after taxation	-356.5	-37.0	127.6	519.6
Add: Depreciation & Amortization	641.0	702.6	800.7	864.1
Net Increase in Current Assets	-53.2	-880.4	-390.3	-475.7
Net Increase in Current Liabilities	-241.9	646.1	120.0	227.0
Others	494.6	573.3	413.2	359.9
CF from Operating activities	483.9	1,004.5	1,071.2	1,494.8
Investments	-355.4	274.0	0.0	0.0
(Purchase)/Sale of Fixed Assets	-964.8	-712.0	-750.0	-600.0
Others	-18.6	4.0	389.4	3.0
CF from Investing activities	-1,338.8	-434.0	-360.6	-597.0
(inc)/Dec in Loan	1,198.4	-971.5	-500.0	-500.0
Dividend & Dividend tax	-67.0	0.0	0.0	0.0
Other	-313.6	549.2	-413.2	-359.9
CF from Financing activities	817.8	-422.4	-913.2	-859.9
Net Cash Flow	-32.0	166.0	-202.6	37.9
Cash and Cash Equivalent	85.2	53.2	356.8	154.2
Cash	53.2	219.2	154.2	192.1
Free Cash Flow	-480.9	292.5	321.2	894.8

Source: Company, ICICI Direct Research

Exhibit 5: Balance Sheet				₹ crore
(Year-end March)	FY23	FY24	FY25E	FY26E
Equity Capital	1,193.3	1,323.0	1,323.0	1,323.0
Reserve and Surplus	5,580.2	6,588.4	6,712.6	7,228.8
Total Shareholders funds	6,773.5	7,911.4	8,035.6	8,551.7
Total Debt	5,637.1	4,710.2	4,210.2	3,710.2
Deferred Tax Liability	219.3	229.2	233.8	238.4
Long-Term Provisions	20.7	32.3	33.0	33.6
Other Non Current Liabilities	180.6	167.9	171.3	174.7
Source of Funds	12,831	13,051	12,684	12,709
Gross Block - Fixed Assets	8,169.0	9,415.9	9,915.9	10,415.9
Accumulated Depreciation	1,807.9	2,548.5	3,349.2	4,213.3
Net Block	6,361.1	6,867.4	6,566.6	6,202.5
Capital WIP	1,418.6	1,115.8	1,365.8	1,465.8
Fixed Assets	7,779.7	7,983.2	7,932.4	7,668.3
Investments	639.0	385.0	385.0	385.0
Goodwill on Consolidation	1,107.5	1,122.6	1,122.6	1,122.6
Other non-Current Assets	238.7	114.9	117.2	119.5
Deferred Tax Assets	349.3	386.5	0.0	0.0
Inventory	1,681.4	2,175.9	2,276.2	2,427.3
Debtors	1,799.3	2,134.4	2,411.4	2,722.7
Other Current Assets	732.1	652.7	665.7	679.0
Cash	195.6	356.8	154.2	192.1
Total Current Assets	4,408.4	5,319.8	5,507.5	6,021.2
Creditors	1,192.7	1,538.4	1,643.9	1,856.2
Provisions	39.2	43.6	44.4	45.3
Other Current Liabilities	459.5	678.9	692.5	706.4
Total Current Liabilities	1,691.4	2,260.9	2,380.9	2,607.9
Net Current Assets	2,716.9	3,058.9	3,126.6	3,413.3
Application of Funds	12,831	13,051	12,684	12,709

Source: Company, ICICI Direct Research

Exhibit 6: Key ratios FY23 FY24 FY25E FY26E (Year-end March) Per share data (₹) Reported EPS 0.1 1.0 3.9 -1.4 Cash EPS -1.4 0.6 1.0 3.9 BV per share 51.3 59.9 60.9 64.8 1.2 Cash per Share 1.5 2.7 1.5 Dividend per share 0.0 0.0 0.0 0.0 **Operating Ratios (%) Gross Profit Margins** 61.8 63.8 64.9 66.1 EBITDA margins 15.1 17.9 8.9 14.6 **PAT Margins** -2.5 1.0 1.4 5.0 Cash Conversion Cycle 118 124 120 115 Asset Turnover 0.9 0.9 0.9 1.0 EBITDA conversion Rate 77.0 84.0 76.6 80.3 Return Ratios (%) -2.7 1.0 1.6 6.1 RoE RoCE 1.4 5.0 5.4 8.7 RoIC -0.5 4.1 5.4 9.2 Valuation Ratios (x) 238.0 58.4 P/E -162.8 1,703.7 EV / EBITDA 28.9 24.5 18.1 56.3 EV / Net Sales 5.0 4.2 3.7 3.2 Market Cap / Sales 4.3 3.7 3.3 2.9 Price to Book Value 4.5 3.8 3.8 3.6 Solvency Ratios 2.0 Debt / EBITDA 9.0 3.9 3.0 Debt / Equity 0.8 0.5 0.4 0.6 **Current Ratio** 2.5 2.2 2.2 2.2 **Quick Ratio** 1.5 1.2 1.3 1.3 Inventory days 87 90 85 97 Debtor days 95 93 95 95 69 65 65 Creditor days 61

Source: Company, ICICI Direct Research

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA(Tech); Vedant Nilekar, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report